CN103344763A - Latex-reinforced AFP detection kit and its preparation method and use - Google Patents
Latex-reinforced AFP detection kit and its preparation method and use Download PDFInfo
- Publication number
- CN103344763A CN103344763A CN2013102400860A CN201310240086A CN103344763A CN 103344763 A CN103344763 A CN 103344763A CN 2013102400860 A CN2013102400860 A CN 2013102400860A CN 201310240086 A CN201310240086 A CN 201310240086A CN 103344763 A CN103344763 A CN 103344763A
- Authority
- CN
- China
- Prior art keywords
- latex
- afp
- reagent
- detection kit
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a latex-reinforced AFP detection kit and its preparation method and use. The latex-reinforced AFP detection kit comprises a R1 reagent, a R2 reagent and a calibration material. The R1 reagent comprises 50-100mmol/L of a Tris buffer solution having a pH value of 7.3-7.5, 3-4% of Dextran 8000-10000, and 20-40mmol/L of ethylene diamine tetraacetic acid. The R2 reagent comprises a mouse anti-human AFP monoclonal antibody, a polystyrene latex coating, a phosphate buffer solution having a pH value of 7.0-7.4 and ethylene diamine tetraacetic acid. The calibration material comprises 0.6-2.2% of sodium azide, 2-8% of Tween-20 and 1-3% of bovine serum albumin. The invention also discloses a preparation method and a detection use of the latex-reinforced AFP detection kit. The latex-reinforced AFP detection kit can be operated simply and has sensitivity, linearity and singularity satisfying practical application requirements.
Description
Technical field
The present invention relates to medical immunology in-vitro diagnosis field, be specifically related to a kind of latex and strengthen AFP detection kit and its preparation method and application.
Background technology
Alpha-fetoprotein (AFP) is mainly synthetic in fetal livers, molecular weight 6.9 ten thousand, and 13 all AFP account for 1/3 of plasma proteins total amount fetus.Reach the top in pregnant 30 weeks, descend gradually later on, during birth in the blood plasma concentration be about 1% of peak period, about 40mg/L, when one full year of life near adult's level (being lower than 30 μ g/L).
AFP can be used for the antenatal detection of fetus in puerpera's amniotic fluid or the parent blood plasma.As when neural-tube defect, spina bifida, the anencephalus etc., AFP can be entered amniotic fluid and be caused its content in amniotic fluid significantly to raise by open nerviduct.Fetus birth defects such as death, teratoma in uterine cavity also can have that AFP increases in the amniotic fluid.AFP can partly enter the parent blood circulation through amniotic fluid.At the parent of 85% spina bifida and anencephalus, plasma A FP has diagnostic value in the visible rising of pregnant 16-18 week, but must be combined with clinical experience, in order to avoid false-positive mistake occurs.
Because the content of Serum AFP is low, its assay method needs higher sensitivity and specificity.By the qualitative detection of initial immunoelectrophoresis, to radio-immunity, fluorescence immunoassay and immunoenzymatic quantitative detection, and the robotization detection of arriving immunoturbidimetry, develop very rapid.Unidirectional immunity diffusion (SRID), radioimmunoassay (RIA), fluorescence immunoassay are sent out (FIA), time-resolved fluorescent immunoassay (TRFIA), chemiluminescence assay.At present, chemiluminescence is the most general method in common, but chemiluminescence instrument costliness, and mainly concentrate on front three hospital, popularization has very big limitation for the AFP project, after the employing latex strengthens immunoturbidimetry, can be generalized to national hospital at different levels.AFP detection kit of the present invention has adopted special latex beads signal amplification technique, and reagent sensitivity can reach 0.5ng/ml, can be applied to full automatic biochemical apparatus fully and detect.
Summary of the invention
The purpose of this invention is to provide a kind of latex and strengthen AFP detection kit detection kit, it is easy and simple to handle, quick, highly sensitive, specificity is good.
The present invention overcomes the existing problem of background technology, has proposed a kind of new latex enhancement mode AFP detection kit, and it comprises R1 reagent, R2 reagent and calibration object.Wherein, R1 reagent comprises: Tris damping fluid 50-100mmol/l, Dextran8000-10000 3-4% and the disodium ethylene diamine tetraacetate 20-40mmol/L of PH7.3-7.5; R2 reagent comprises: the phosphate buffer of mouse-anti people AFP monoclonal antibody, polystyrene latex bag quilt, PH7.0-7.4 and disodium ethylene diamine tetraacetate etc.; Calibration object comprises: Sodium azide 0.6-2.2%, Tween-20 2-8%, bovine serum albumin(BSA) 1-3%.Among the present invention, above-mentioned number percent is the number percent of cow's serum matrix volumetric usage.
In the latex enhancement mode AFP detection kit of the present invention, the mouse-anti people AFP monoclonal antibody in the described R2 reagent and the mass ratio of polystyrene latex bag quilt are 1/10-2/10.
In the latex enhancement mode AFP detection kit of the present invention, adopt Nano microsphere Sheet clonal antibody, improved reagent sensitivity, can be directly used in automatic clinical chemistry analyzer.
The invention allows for the preparation method of latex enhancement mode AFP detection kit, comprise reagent R1 preparation, reagent R2 preparation.
The preparation process of described R1 reagent is: successively following ingredients Tris damping fluid 50-100mmol/l, Dextran8000-10000 3-4% and disodium ethylene diamine tetraacetate 20-40mmol/L dissolving are regulated pH value to 7.3-7.5.
The preparation process of described R2 reagent is: the polystyrene latex particles of mouse-anti people AFP monoclonal antibody and the 180-220nm mass ratio with 30: 100 is mixed, damping fluid adopts the phosphate buffer of 0.02M, with behind both mixings 37 ℃ absorption 8 hours, the antibody that does not connect is removed in dialysis afterwards, the glycocoll that adds confining liquid 0.1% bovine serum albumin(BSA) and 0.2mm, sealed 2 hours, the centrifugal supernatant that goes, with PH7.4 phosphate buffer 45mmol/l, disodium ethylene diamine tetraacetate 10.2mmol/l, 0.05% bovine serum albumin(BSA), 0.9%NaN3 is diluted to 0.18%.
Wherein, in the antibody sandwich process, the confining liquid component comprises the glycocoll of 0.6-1.2% bovine serum albumin(BSA), 10-50mm in described R2 reagent, and latex dilution component comprises PH7.0-7.6 phosphate buffer 30-80mmol/l, the 0.5-1.5% bovine serum albumin(BSA), 0.9%NaN3.
Described calibration object preparation process is: with treated cow's serum, add BAS0.1%, NaN30.9% obtains the calibration object dilution.
The invention allows for the application of latex enhancement mode AFP detection kit in detecting AFP.Latex enhancement mode AFP detection kit of the present invention can directly be used at automatic clinical chemistry analyzer.
Beneficial effect of the present invention comprises: easy and simple to handle, quick, highly sensitive, specificity is good.
Description of drawings
Fig. 1 is the reagent calibration curve synoptic diagram of the present invention of embodiment 1.
Fig. 2 is embodiment 3 serum correlativity synoptic diagram.
Embodiment
In conjunction with following specific embodiments and the drawings, the present invention is described in further detail, and protection content of the present invention is not limited to following examples.Under the spirit and scope that do not deviate from inventive concept, the variation that those skilled in the art can expect and advantage portion are included in the present invention, and are protection domain with the appending claims.Implement process of the present invention, condition, reagent, experimental technique etc., except the following content of mentioning specially, be universal knowledege and the common practise of this area, the present invention is not particularly limited content.
Latex enhancement mode AFP detection kit of the present invention comprises R1 reagent, R2 reagent and calibration object.Phosphate buffer 50-100mmol/l, the Dextran8000-100003-4% of consisting of of R1 reagent: PH=7.3-7.5 and disodium ethylene diamine tetraacetate 20-40mmol/L; Consisting of of R2 reagent: the phosphate buffer of mouse-anti people AFP monoclonal antibody, polystyrene latex bag quilt, PH=7.0-7.4 and disodium ethylene diamine tetraacetate etc., consisting of of calibration object: 0-1500ng/l cow's serum matrix, Sodium azide 0.2-2.2%, Tween-20 1-10%, bovine serum albumin(BSA) 1-3%, above-mentioned number percent are the number percent of cow's serum matrix volumetric usage.
Mouse-anti people AFP monoclonal antibody and polystyrene latex bag are 1/10-2/10 by mass ratio in the R2 reagent.Preferably, mouse-anti people AFP monoclonal antibody and polystyrene latex bag are 1/10 by mass ratio in the R2 reagent.
Among the present invention, adopt the pipe/polyhenylethylene nano microballoon as the monoclonal antibody carrier, prepare latex enhancement mode AFP detection kit.
The preparation process of R1 reagent is: successively following ingredients Tris50mmol/l, Dextran80003.5% and disodium ethylene diamine tetraacetate 20mmol/L dissolving are regulated pH value to 7.3.
The preparation process of R2 reagent is: the polystyrene latex particles of mouse-anti people AFP monoclonal antibody and the 180-220nm mass ratio with 10: 100 is mixed, damping fluid adopts the phosphate buffer of 0.02M, with behind both mixings 37 ℃ absorption 8 hours, the antibody that does not connect is removed in dialysis afterwards, the glycocoll that adds confining liquid 0.1% bovine serum albumin(BSA) and 0.2mm, sealed 2 hours, the centrifugal supernatant that goes, with PH7.4 phosphate buffer 45mmol/l, disodium ethylene diamine tetraacetate 10.2mmol/l, 0.05% bovine serum albumin(BSA), 0.9%NaN3 is diluted to 0.18%.
Wherein, in the antibody sandwich process, the confining liquid component comprises the glycocoll of 0.6%-1.2% bovine serum albumin(BSA), 10-50mm in the R2 reagent, and latex dilution component comprises PH7.0-7.6 phosphate buffer 30-80mmol/l, the 0.5%-1.5% bovine serum albumin(BSA), 0.9%NaN3.
The calibration object preparation process is: with treated cow's serum, add BSA0.1%, NaN30.9% obtains the calibration object dilution.
Latex enhancement mode AFP detection kit of the present invention is that example detects analysis with Hitachi's 7170 automatic clinical chemistry analyzers in detecting application.
Embodiment 1: bracketing
Use the reagent of latex enhancement mode AFP detection kit of the present invention, adopt 7170 automatic clinical chemistry analyzers to calibrate, test parameters is seen 7170 set factors tables 1.
7170 automatic clinical chemistry analyzer set factors following (table 1):
| Project | Parameter |
| Wavelength (master/pair) | 700nm/NULL |
| Application of sample is than (sample: R1: R2) | 20∶180∶60 |
| The photometry point | 18-34 |
| Calibration mode | Spline |
Experimental result as shown in Figure 1, calibration curve is level and smooth, shows that kit calibrates successfully.
Embodiment 2: the lowest detectable limit test
Use the reagent of this law invention latex enhancement mode AFP detection kit, after reagent is calibrated successfully, be that the 4ng/ml sample is diluted to 0.5ng/ml, 1ng/ml, 2ng/ml respectively with physiological saline with concentration, the sample after the dilution is measured respectively on biochemical instruments 5 times, calculate CV, SD.CV is less than 15%, the MEAN that surveys both can think greater than SD and can measure concentration.
Table 2
The result finds out by table 2, and reagent lowest detectable limit of the present invention has reached 0.5ng/ml.
Embodiment 3: the serum correlation test
Use this law invention reagent and the Japanese Tosoh Corporation alpha-fetoprotein AFP of company detection kit (fluorescence magnetic particle enzyme is exempted from method) to carry out the serum correlation analysis.The Japan Tosoh Corporation AFP of company detection kit adopts Japanese Tosoh Corporation Chemiluminescence Apparatus AIA1800 to go up and measures, and according to the said firm's operation instructions, 100 parts of human serums is measured.Same reagent of the present invention is measured this 100 routine serum (parameter sees Table 1) at Hitachi's 7170 full automatic biochemical apparatus, measured value is carried out correlation analysis, according to above-mentioned " AFP assay method " in parameter carry out measurement result and see Fig. 2, X, Y-axis is measured value (the content ng/ml of AFP).
Result by Fig. 2 finds out that latex enhancement mode AFP detection kit of the present invention is R2=0.994 with the relevant of contrast agents, and regression equation is y=1.0418x+3.1901.The result shows that reagent of the present invention compares with the Japanese Tosoh Corporation alpha-fetoprotein AFP of company detection kit, and it is good to measure patients serum's correlativity, and specificity is consistent.
Claims (5)
1. a latex enhancement mode AFP detection kit is characterized in that, comprises R1 reagent, R2 reagent, calibration object;
Wherein, described R1 reagent comprises: Tris damping fluid 50-100mmol/l, Dextran8000-100003-4% and the disodium ethylene diamine tetraacetate 20-40mmol/L of PH7.3-7.5;
Described R2 reagent comprises: phosphate buffer and the disodium ethylene diamine tetraacetate of mouse-anti people AFP monoclonal antibody, polystyrene latex bag quilt, PH7.0-7.4;
Described calibration object comprises: Sodium azide 0.6-2.2%, Tween-20 2-8%, bovine serum albumin(BSA) 1-3%.
2. latex enhancement mode AFP detection kit as claimed in claim 1 is characterized in that, in the described R2 reagent, the mass ratio of described mouse-anti people AFP monoclonal antibody and described polystyrene latex bag quilt is 1/10-2/10.
3. the preparation method of a latex enhancement mode AFP detection kit is characterized in that, adopts the pipe/polyhenylethylene nano microballoon as the monoclonal antibody carrier, prepares latex enhancement mode AFP detection kit as claimed in claim 1; Comprise:
Preparation R1 reagent: Tris50mmol/l, Dextran 8,000 3.5% and disodium ethylene diamine tetraacetate 20mmol/L dissolving are regulated pH value to 7.3;
Preparation R2 reagent: the polystyrene latex particles of mouse-anti people AFP monoclonal antibody and the 180-220nm mass ratio with 10: 100 is mixed, damping fluid adopts the phosphate buffer of 0.02M, with behind both mixings 37 ℃ absorption 8 hours, the antibody that does not connect is removed in dialysis afterwards, the glycocoll that adds confining liquid 0.1% bovine serum albumin(BSA) and 0.2mm, sealed 2 hours, the centrifugal supernatant that goes, with PH7.4 phosphate buffer 45mmol/l, disodium ethylene diamine tetraacetate 10.2mmol/l, 0.05% bovine serum albumin(BSA), 0.9%NaN3 is diluted to 0.18%;
The preparation calibration object: with treated cow's serum, add BSA 0.1%, NaN3 0.9% obtains the calibration object dilution.
4. preparation method as claimed in claim 3, it is characterized in that, in the antibody sandwich process, the confining liquid component comprises the glycocoll of 0.6-1.2% bovine serum albumin(BSA), 10-50mm, latex dilution component comprises PH7.0-7.6 phosphate buffer 30-80mmol/l, the 0.5-1.5% bovine serum albumin(BSA), 0.9%NaN3.
5. the application of latex enhancement mode AFP detection kit in detecting AFP.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102400860A CN103344763A (en) | 2013-06-18 | 2013-06-18 | Latex-reinforced AFP detection kit and its preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102400860A CN103344763A (en) | 2013-06-18 | 2013-06-18 | Latex-reinforced AFP detection kit and its preparation method and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103344763A true CN103344763A (en) | 2013-10-09 |
Family
ID=49279577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102400860A Pending CN103344763A (en) | 2013-06-18 | 2013-06-18 | Latex-reinforced AFP detection kit and its preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103344763A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103852580A (en) * | 2014-02-18 | 2014-06-11 | 温州市康泰生物科技有限公司 | Staphylococcus aureus identification kit and preparation method thereof |
| CN106596963A (en) * | 2016-05-27 | 2017-04-26 | 安徽伊普诺康生物技术股份有限公司 | Kit for measuring alpha fetoprotein |
| CN107543931A (en) * | 2017-09-12 | 2018-01-05 | 四川新健康成生物股份有限公司 | Kit based on latex enhancing immune turbidimetry detection TnI and preparation method thereof |
| CN109633161A (en) * | 2018-11-22 | 2019-04-16 | 深圳上泰生物工程有限公司 | A kind of Procalcitonin detection kit based on latex enhancing immune turbidimetry |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1026622A (en) * | 1996-05-10 | 1998-01-27 | Sekisui Chem Co Ltd | Determination method for human alpha-fetoproteins and measuring kit |
| JP2001091516A (en) * | 1999-09-24 | 2001-04-06 | Sekisui Chem Co Ltd | METHOD FOR DETERMINING QUANTITY OF HUMAN alpha-FETOPROTEIN AND MEASUREMENT KIT |
| CN101833010A (en) * | 2010-03-29 | 2010-09-15 | 上海太阳生物技术有限公司 | Kit for detecting fibrin (ogen) degradation products (FDP) (by using emulsion immunoturbidimetry) |
| CN101893619A (en) * | 2010-02-10 | 2010-11-24 | 上海蓝怡科技有限公司 | Method for improving stability of latex suspension liquid |
| CN102128924A (en) * | 2010-01-12 | 2011-07-20 | 上海景源医疗器械有限公司 | Agent kit for measuring urinary transferrin by latex-enhanced immunoturbidimetry and preparation method thereof |
| CN102621325A (en) * | 2012-04-06 | 2012-08-01 | 上海蓝怡科技有限公司 | Kit for detecting concentration of docetaxel in blood |
| CN102621332A (en) * | 2012-04-06 | 2012-08-01 | 上海蓝怡科技有限公司 | Retinol binding protein assay kit based on latex particle coating |
| CN102662061A (en) * | 2012-04-17 | 2012-09-12 | 北京九强生物技术股份有限公司 | Kit for determination of human alpha-fetoprotein content by latex-enhanced immunoturbidimetry |
| CN102998445A (en) * | 2012-12-12 | 2013-03-27 | 元升生物科技（上海）有限公司 | Reagent and preparation method for determining glycocholic acid |
-
2013
- 2013-06-18 CN CN2013102400860A patent/CN103344763A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1026622A (en) * | 1996-05-10 | 1998-01-27 | Sekisui Chem Co Ltd | Determination method for human alpha-fetoproteins and measuring kit |
| JP2001091516A (en) * | 1999-09-24 | 2001-04-06 | Sekisui Chem Co Ltd | METHOD FOR DETERMINING QUANTITY OF HUMAN alpha-FETOPROTEIN AND MEASUREMENT KIT |
| CN102128924A (en) * | 2010-01-12 | 2011-07-20 | 上海景源医疗器械有限公司 | Agent kit for measuring urinary transferrin by latex-enhanced immunoturbidimetry and preparation method thereof |
| CN101893619A (en) * | 2010-02-10 | 2010-11-24 | 上海蓝怡科技有限公司 | Method for improving stability of latex suspension liquid |
| CN101833010A (en) * | 2010-03-29 | 2010-09-15 | 上海太阳生物技术有限公司 | Kit for detecting fibrin (ogen) degradation products (FDP) (by using emulsion immunoturbidimetry) |
| CN102621325A (en) * | 2012-04-06 | 2012-08-01 | 上海蓝怡科技有限公司 | Kit for detecting concentration of docetaxel in blood |
| CN102621332A (en) * | 2012-04-06 | 2012-08-01 | 上海蓝怡科技有限公司 | Retinol binding protein assay kit based on latex particle coating |
| CN102662061A (en) * | 2012-04-17 | 2012-09-12 | 北京九强生物技术股份有限公司 | Kit for determination of human alpha-fetoprotein content by latex-enhanced immunoturbidimetry |
| CN102998445A (en) * | 2012-12-12 | 2013-03-27 | 元升生物科技（上海）有限公司 | Reagent and preparation method for determining glycocholic acid |
Non-Patent Citations (2)
| Title |
|---|
| 陆晓荣 等: "胶乳增强免疫比浊法在甲胎蛋白测定的方法学评价", 《国际检验医学杂志》 * |
| 陈浩全 等: "乳胶粒子法检测甲胎蛋白的应用", 《中国卫生检验杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103852580A (en) * | 2014-02-18 | 2014-06-11 | 温州市康泰生物科技有限公司 | Staphylococcus aureus identification kit and preparation method thereof |
| CN103852580B (en) * | 2014-02-18 | 2015-12-09 | 温州市康泰生物科技有限公司 | Staphylococcus aureus identification kit and preparation method thereof |
| CN106596963A (en) * | 2016-05-27 | 2017-04-26 | 安徽伊普诺康生物技术股份有限公司 | Kit for measuring alpha fetoprotein |
| CN107543931A (en) * | 2017-09-12 | 2018-01-05 | 四川新健康成生物股份有限公司 | Kit based on latex enhancing immune turbidimetry detection TnI and preparation method thereof |
| CN107543931B (en) * | 2017-09-12 | 2020-02-21 | 四川新健康成生物股份有限公司 | Kit for detecting TnI based on latex enhanced immunoturbidimetry and preparation method thereof |
| CN109633161A (en) * | 2018-11-22 | 2019-04-16 | 深圳上泰生物工程有限公司 | A kind of Procalcitonin detection kit based on latex enhancing immune turbidimetry |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018120620A1 (en) | Fluorescence immunochromatographic detection card and preparation method therefor and use thereof | |
| Fan et al. | Chemiluminescence immunoassay based on microfluidic chips for α-fetoprotein | |
| CN102967706B (en) | Preparation method and application of flow injection chemiluminiscence immuno sensor for detecting tumor marker | |
| WO2021185124A1 (en) | Use of vitamin d binding protein as marker in diagnosis of mental illness depression | |
| CN111337691B (en) | Sensitive and stable serum procalcitonin determination kit and preparation method and application thereof | |
| CN108613977B (en) | N-terminal brain natriuretic peptide precursor detection kit | |
| CN103344763A (en) | Latex-reinforced AFP detection kit and its preparation method and use | |
| CN107389919A (en) | A kind of label-free fluorescence aptamer sensor and its preparation method and application | |
| CN107121548A (en) | Quantitatively detect test paper, preparation method and the detection method of tumor markers | |
| CN105759057A (en) | Dry-type immunofluorescence kit for detecting Alzheimer syndrome MS4A6A and preparation method thereof | |
| CN109444427A (en) | A kind of kit detecting human parvovirus IgM antibody | |
| Adigun et al. | Alpha fetoprotein | |
| CN107656069A (en) | Full-range C reactive protein quantitative detecting reagent and method in whole blood | |
| CN106370860A (en) | Kit and test paper strip for serum immunoglobulin E colloidal gold chromatography quantitative detection | |
| CN105548547A (en) | Flow type array immunoassay kit for detecting lung cancer markers based on flow cytometry | |
| WO2021147453A1 (en) | Quantitative kit for myxovirus resistance protein 1 | |
| CN103901188B (en) | A kind of chemical luminescent analysis reagent kid sucking anaphylactogen and preparation method thereof and detection method | |
| Chang et al. | Facile colorimetric detection of human chorionic gonadotropin based on the peptide-induced aggregation of gold nanoparticles | |
| Liu et al. | Procalcitonin measurement using antibody-conjugated fluorescent microspheres distinguishes atypical bacterial meningitis from viral encephalitis in children | |
| CN104155458A (en) | Quantitative detection kit for human chorionic gonadotropin and application of quantitative detection kit | |
| CN110907442A (en) | Colorimetric detection kit and detection method for milk allergen | |
| US20190011451A1 (en) | Methods and compositions for assaying blood levels of legumain | |
| CN108267594A (en) | A kind of ST2 detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| CN204422542U (en) | Two len antibodies inspect paper slip soon | |
| US20110189777A1 (en) | Methods and compositions for improved diagnostic assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131009 |